Modulating the TREGs Pathway in ALS: Unveiling Innate Immunity’s Role in Neurodegeneration
Time: 1:30 pm
day: Conference Day Two Track B PM
Details:
- Understanding regulatory T cells (TREGs) and their role in contributing to neuroinflammation and neurodegeneration via adaptive and immune cell activation in ALS
- Exploring efficacy in targeting CD40L to increase the polarization of lymphocytes in TREGs upstream to suppress neuroinflammation inducing neuroprotection and restoring function in ALS patients
- Unveiling new interim Phase 2 trial results to highlight early safety and efficacy signals in patients
- Reviewing proinflammatory biomarker data and correlations with clinical endpoints
